- Baxter Pharma $BAX held its 2q2011 earnings conference call on 7/21/2011 - click here for transcript link.
- BAX acquired the rights to Captisol-enabled Nexterone (marketed product for atrial fibrillation) via its acquisition of Prism Pharma, which had licensed the product from Ligand (see details on LGND research page).
- Quote from prepared remarks: "We also completed the acquisition of Prism Pharmaceuticals and launched NEXTERONE, the first and only ready-to-use premixed formulation of the antiarrhythmic agent amiodarone. Given this drug is typically administered to patients in extremely time-sensitive situations, the benefits of the ready-to-use premixed form allows for immediate use and reduces the potential risk of medication errors. We believe this unique product satisfies unmet clinical needs, offers an opportunity to expand the current market, enhance the potential for application in additional geographies outside the United States."
- Quotes from Q&A session:
Michael Matson - Mizuho Securities: "Just wondering on the NEXTERONE product that you acquired. Can you maybe comment on to what degree that contributed to revenue in the quarter? Then just, I guess the more important part of the question would be, how big is that market opportunity currently?"
Robert L. Parkinson, Jr. - Chairman and CEO: "Yeah, I mean, the contribution was – we just [launched] the product. There was virtually no contribution to the results in Q2, nor an outlook for that product. The initial reception is very good and I don't know if we'd quantified when we did the deal, Mary Kay, what we think in the long-term projections. Is this immaterial?"
Mary Kay Ladone - Corporate VP, IR: "Yeah. I mean, given the fact that it's a premix form, we are out with price premium on the product, which will help expand the current market potential, as well as we're looking at additional geographies to launch in. We peg the market opportunity at about $150 million to $200 million globally"